SCHEMBL4927494

SCHEMBL4927494

Cc1ccc(S(=O)(=O)N(O)[C@@H](CN)C(N)=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 2/20 0.47
NFE2L2 Q16236 2/20 0.47
ALDH1A1 P00352 1/20 0.45
AGER Q15109 1/20 0.45
HPGD P15428 1/20 0.43
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
MAPT P10636 1/20 0.40
MCOLN3 Q8TDD5 1/20 0.40
GAA P10253 1/20 0.40
PLAU P00749 1/20 0.40
GLA P06280 1/20 0.40
F2 P00734 1/20 0.39
PRSS1 P07477 1/20 0.39
PRSS2 P07478 1/20 0.39
PRSS3 P35030 1/20 0.39
MCL1 Q07820 1/20 0.39
HCRTR2 O43614 1/20 0.39
POLB P06746 1/20 0.39
PPARG P37231 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5182397 0.87 KEAP1 (0.46) KEAP1NFE2L2ALDH1A1AGERHPGD
SCHEMBL4916977 0.76 ALDH1A1 (0.41) KEAP1NFE2L2ALDH1A1AGERHPGD
SCHEMBL3278846 0.75 AGER (0.53) KEAP1NFE2L2ALDH1A1AGERKMT2A
SCHEMBL31195348 0.72 ALDH1A1 (0.50) KEAP1NFE2L2ALDH1A1AGERHPGD
SCHEMBL4925174 0.71 CA2 (0.46) KEAP1NFE2L2ALDH1A1F2
SCHEMBL5182284 0.71 ALDH1A1 (0.54) KEAP1NFE2L2ALDH1A1AGERHPGD
SCHEMBL3805492 0.71 MEN1 (0.43) KEAP1NFE2L2ALDH1A1AGERHPGD
SCHEMBL8446610 0.71 CA12 (0.48) KEAP1NFE2L2ALDH1A1AGERKMT2A
SCHEMBL8446570 0.71 CA12 (0.48) KEAP1NFE2L2ALDH1A1AGERKMT2A
SCHEMBL8445774 0.70 ATM (0.42) KEAP1NFE2L2ALDH1A1AGERKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2008-10-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 KEAP1 198/4885NFE2L2 1336/4885ALDH1A1 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.